Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals CofiledCriticalTakeda Pharmaceuticals Co
Publication of AR124709A2publicationCriticalpatent/AR124709A2/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Métodos para tratar los trastornos de la coagulación, entre los que se incluyen la hemofilia y la enfermedad de von Willebrand, que comprenden la administración del factor de von Willebrand, solo o en combinación con el factor VIII. Reivindicación 1: Un factor de von Willebrand recombinante (rVWF) para uso en un método para tratar la enfermedad de von Willebrand o la hemofilia A en un sujeto que lo necesita, caracterizado porque el rVWF no está modificado con un polímero soluble en agua, y el rVWF es una composición de multímeros de VWF de alto peso molecular que comprende al menos un 20% de decámeros de VWF o multímeros de orden superior.Methods of treating coagulation disorders, including hemophilia and von Willebrand disease, involving administration of von Willebrand factor, alone or in combination with factor VIII. Claim 1: A recombinant von Willebrand factor (rVWF) for use in a method of treating von Willebrand disease or hemophilia A in a subject in need thereof, characterized in that the rVWF is not modified with a water-soluble polymer, and rVWF is a high molecular weight VWF multimer composition comprising at least 20% VWF decamer or higher order multimers.
ARP220100161A2011-06-102022-01-27
RECOMBINANT VON WILLEBRAND FACTOR (rVWF) USEFUL IN VON WILLEBRAND DISEASE OR HEMOPHILIA A
AR124709A2
(en)
cxcr7 antagonists, their use, pharmaceutical composition, as well as methods for detecting high levels of cxcr7 in a sample and for imaging a tumor, organ, or tissue
acrylate-derived main chain-containing polymer, methods for preparing polymers, pharmaceutical formulations and methods for increasing the solubility of a drug
"nucleic acid, vaccine, pharmaceutical composition, use of a nucleic acid and method for stimulating an immunoresponse versus a t-cell epitope"